Zacks: Analysts Anticipate Ionis Pharmaceuticals (IONS) Will Post Earnings of -$0.11 Per Share

Wall Street analysts forecast that Ionis Pharmaceuticals (NASDAQ:IONS) will report earnings per share of ($0.11) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Ionis Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.01) and the lowest estimate coming in at ($0.25). Ionis Pharmaceuticals posted earnings per share of $0.03 in the same quarter last year, which would indicate a negative year over year growth rate of 466.7%. The firm is expected to report its next earnings results on Tuesday, May 8th.

On average, analysts expect that Ionis Pharmaceuticals will report full year earnings of ($0.13) per share for the current fiscal year, with EPS estimates ranging from ($1.10) to $0.46. For the next fiscal year, analysts anticipate that the company will post earnings of ($0.05) per share, with EPS estimates ranging from ($1.07) to $1.76. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Ionis Pharmaceuticals.

How to Become a New Pot Stock Millionaire

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.10. The company had revenue of $172.00 million during the quarter, compared to analysts’ expectations of $126.38 million. Ionis Pharmaceuticals had a negative net margin of 1.18% and a negative return on equity of 1.94%. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.33 EPS.

Several brokerages have commented on IONS. ValuEngine upgraded shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, March 8th. TheStreet cut shares of Ionis Pharmaceuticals from a “c” rating to a “d+” rating in a research report on Tuesday, February 27th. Zacks Investment Research cut shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 28th. BidaskClub upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, March 9th. Finally, BMO Capital Markets upped their target price on shares of Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, February 28th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $52.15.

Shares of Ionis Pharmaceuticals stock opened at $43.47 on Friday. The firm has a market cap of $5,471.78, a price-to-earnings ratio of 543.38 and a beta of 2.50. Ionis Pharmaceuticals has a 52 week low of $40.33 and a 52 week high of $65.51. The company has a debt-to-equity ratio of 1.45, a current ratio of 5.20 and a quick ratio of 5.15.

In other news, SVP C Frank Bennett sold 12,500 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $52.50, for a total value of $656,250.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Patrick R. O’neil sold 645 shares of the business’s stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $55.00, for a total transaction of $35,475.00. Following the completion of the transaction, the senior vice president now directly owns 15,097 shares of the company’s stock, valued at approximately $830,335. The disclosure for this sale can be found here. Insiders sold a total of 38,500 shares of company stock valued at $2,017,410 in the last three months. 2.13% of the stock is owned by company insiders.

Several hedge funds have recently made changes to their positions in IONS. The Manufacturers Life Insurance Company boosted its stake in Ionis Pharmaceuticals by 9.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock worth $190,000 after purchasing an additional 311 shares during the period. Great West Life Assurance Co. Can boosted its stake in Ionis Pharmaceuticals by 9.0% in the 3rd quarter. Great West Life Assurance Co. Can now owns 13,296 shares of the company’s stock worth $698,000 after purchasing an additional 1,096 shares during the period. Hanseatic Management Services Inc. boosted its stake in Ionis Pharmaceuticals by 41.1% in the 4th quarter. Hanseatic Management Services Inc. now owns 4,154 shares of the company’s stock worth $209,000 after purchasing an additional 1,210 shares during the period. Amalgamated Bank boosted its stake in Ionis Pharmaceuticals by 5.8% in the 4th quarter. Amalgamated Bank now owns 24,702 shares of the company’s stock worth $1,243,000 after purchasing an additional 1,350 shares during the period. Finally, Teachers Advisors LLC boosted its stake in Ionis Pharmaceuticals by 1.4% in the 4th quarter. Teachers Advisors LLC now owns 134,007 shares of the company’s stock worth $6,741,000 after purchasing an additional 1,913 shares during the period. 90.91% of the stock is owned by institutional investors.

WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/17/zacks-analysts-anticipate-ionis-pharmaceuticals-ions-will-post-earnings-of-0-11-per-share.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Get a free copy of the Zacks research report on Ionis Pharmaceuticals (IONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply